Prosecution Insights
Prosecution Insights
48 pending office actions • 28 art units • 45 examiners • 1 of 48 (2%) have an AI response strategy ready • 78 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 22 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 22 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (8%) |
| §103 only | 12 (25%) |
| §102 only | 2 (4%) |
| §112 only | 7 (15%) |
| Double-patenting only | 3 (6%) |
| Double-patenting + other | 6 (12%) |
| Multi-statute (no §101) | 14 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 2 | 62.7% | +36.9% |
| HADDAD, MAHER M | 2 | 50.5% | +53.9% |
| KIM, YUNSOO | 2 | 65.8% | +34.8% |
| DAVIS, RUTH A | 1 | 60.7% | +31.2% |
| SHIM, DAVID M. | 1 | 57.8% | +55.9% |
| EISENBERG, REBECCA E | 1 | 81.0% | +12.2% |
| ORWIG, KEVIN S | 1 | 25.2% | +39.8% |
| DROUIN, STEVE HOANG | 1 | 100.0% | +0.0% |
| TAVERNINI, BREANNA MARIE | 1 | — | — |
| MOORE, JOHN DAVID | 1 | 65.4% | +23.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769452 | METHOD FOR EVALUATING DRUG TOXICITY | MARTIN, RACHEL E | 127d overdue |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | STEELE, AMBER D | 89d overdue |
| 18037834 | FLUID DELIVERY DEVICES AND METHODS THEREOF | LANGE, ERIC A | 28d overdue |
| 18029026 | PARATHYROID GLAND CELLS | BEHARRY, ZANNA MARIA | 24d overdue |
| 17778611 | T-CELL MASTER CELL BANK | ZHU, JIANJIAN | 23d overdue |
| 17596421 | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY | FAUST, AMBER KATHLEEN | 8d overdue |
| 17995198 | Subcutaneous Port With Locking Member | STIGELL, THEODORE J | 9d |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | BUTTICE, AUDREY L | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030901 | THERAPEUTIC AGENT FOR IMMUNE/INFLAMMATORY DISEASE | SZPERKA, MICHAEL EDWARD | 8d |
| 18046450 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | KIM, YUNSOO | 54d |
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | — |
| 18850466 | TYK2 INHIBITORS AND USES THEREOF | SHIM, DAVID M. | — |
| 18723698 | PARTICLE PREVENTION ADAPTER SYSTEM FOR INJECTION PEN | EISENBERG, REBECCA E | — |
| 18662935 | COMBINATIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF IMMUNE GLOBULIN AND HYALURONIDASE | ORWIG, KEVIN S | — |
| 18695720 | METHOD FOR PRODUCING T CELL | MOORE, JOHN DAVID | — |
| 18544966 | EVALUATION, ASSAYS AND TREATMENT OF PKALMEDIATED DISORDERS | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1627 | 2 |
| 1656 | 2 |
| 1622 | 2 |
| 1631 | 2 |
| 1647 | 2 |
| 3783 | 2 |
| 1657 | 2 |
| 1658 | 2 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | 1699 | §102§112Other | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18850466 | TYK2 INHIBITORS AND USES THEREOF | SHIM, DAVID M. | — | §103 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18723698 | PARTICLE PREVENTION ADAPTER SYSTEM FOR INJECTION PEN | EISENBERG, REBECCA E | 3781 | §102§103Other | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18662935 | COMBINATIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF IMMUNE GLOBULIN AND HYALURONIDASE | ORWIG, KEVIN S | 3991 | DP | Non-Final OA | — | Pending | May 13, 2024 |
| 18657004 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | DROUIN, STEVE HOANG | 1627 | §101DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18697196 | METHOD FOR MEASURING CELL CONCENTRATION | TAVERNINI, BREANNA MARIE | — | §103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18695720 | METHOD FOR PRODUCING T CELL | MOORE, JOHN DAVID | — | §101§103§112DP | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18691573 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | HOLLAND, PAUL J | 1656 | §102 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18689723 | INFUSION PUMP | SCHMIDT, EMILY LOUISE | — | §102 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18592897 | HETEROCYCLIC COMPOUND AND USE THEREOF | HABTE, KAHSAY | 1624 | DP | Non-Final OA | — | AI Ready | Mar 01, 2024 |
| 18684541 | SELECTIVE MEASUREMENT OF HUMAN FACTOR VIII | THOMPSON, CURTIS A | — | §103 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18292586 | ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF | TAYLOR, LIA ELAN | — | §102§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18544966 | EVALUATION, ASSAYS AND TREATMENT OF PKALMEDIATED DISORDERS | SZPERKA, MICHAEL EDWARD | — | §112DP | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18545528 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE | NOAKES, SUZANNE MARIE | 1656 | §102§112 | Non-Final OA | 75d | Pending | Dec 19, 2023 |
| 18379047 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | LAU, JONATHAN S | 1693 | §103Other | Non-Final OA | 9d | Pending | Oct 11, 2023 |
| 18482522 | ANTIBODIES TARGETING COMPLEMENT FACTOR D AND USES THEROF | REDDIG, PETER J | 1646 | §112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §112DP | Final Rejection | 79d overdue | Pending | Sep 14, 2023 |
| 18550486 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | ELENISTE, PIERRE PAUL | 1622 | §102§112 | Non-Final OA | 69d | Pending | Sep 14, 2023 |
| 18231982 | FORMULATIONS COMPRISING GLUCOCEREBROSIDASE AND ISOFAGOMINE | CURRENS, GRANT CARSON | 1651 | §103DPOther | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18361790 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF IMMUNE CELLS | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103§112 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | BUTTICE, AUDREY L | 1647 | §103§112Other | Non-Final OA | 16d | Pending | Jun 13, 2023 |
| 18256565 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | HADDAD, MAHER M | 1641 | §112DP | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18037834 | FLUID DELIVERY DEVICES AND METHODS THEREOF | LANGE, ERIC A | 3783 | §102§103 | Non-Final OA | 28d overdue | Pending | May 19, 2023 |
| 18318218 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | May 16, 2023 |
| 18029026 | PARATHYROID GLAND CELLS | BEHARRY, ZANNA MARIA | 1632 | §102§103§112 | Non-Final OA | 24d overdue | Pending | Apr 11, 2023 |
| 18030901 | THERAPEUTIC AGENT FOR IMMUNE/INFLAMMATORY DISEASE | SZPERKA, MICHAEL EDWARD | 1641 | §112 | Final Rejection | 8d | Pending | Apr 07, 2023 |
| 18025315 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | 76d | Pending | Mar 08, 2023 |
| 18046450 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | KIM, YUNSOO | 1641 | §103Other | Final Rejection | 54d | Pending | Oct 13, 2022 |
| 17916441 | ADAMTS13 VARIANT, COMPOSITIONS, AND USES THEREOF | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | 72d overdue | Pending | Sep 30, 2022 |
| 17995198 | Subcutaneous Port With Locking Member | STIGELL, THEODORE J | 3783 | §102§103 | Non-Final OA | 9d | Pending | Sep 30, 2022 |
| 17759992 | TREATMENT OF MENORRHAGIA IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF | BARSKY, JARED | 1628 | §103§112 | Non-Final OA | — | Pending | Aug 02, 2022 |
| 17778611 | T-CELL MASTER CELL BANK | ZHU, JIANJIAN | 1631 | §103§112Other | Non-Final OA | 23d overdue | Pending | May 20, 2022 |
| 17773467 | METHOD FOR PRODUCING T CELLS | ABBOTT, KODYE LEE | 1634 | §112 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17769452 | METHOD FOR EVALUATING DRUG TOXICITY | MARTIN, RACHEL E | 1657 | §101§103§112 | Non-Final OA | 127d overdue | Pending | Apr 15, 2022 |
| 17672748 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | OGUNBIYI, OLUWATOSIN A | 1645 | §103 | Non-Final OA | 51d overdue | Pending | Feb 16, 2022 |
| 17622580 | TRANSFECTION METHOD | MEJIAS, SAMANTHA LEE | 1618 | §103Other | Non-Final OA | 15d | Pending | Dec 23, 2021 |
| 17622585 | TRANSFECTION METHOD | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | — | Pending | Dec 23, 2021 |
| 17596422 | ANTIBODY PURIFICATION METHODS AND COMPOSITIONS THEREOF | EDWARDS, JESSICA FAYE | 1657 | §103Other | Final Rejection | 23d | Pending | Dec 09, 2021 |
| 17596421 | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY | FAUST, AMBER KATHLEEN | 1643 | §103§112 | Final Rejection | 8d overdue | Pending | Dec 09, 2021 |
| 17362191 | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) | AUDET, MAURY A | 1654 | §103 | Final Rejection | 79d | Pending | Jun 29, 2021 |
| 17416859 | T-CELL RECEPTOR MODIFIED OBJECT | GEORGE, DENNIS CHERIAN | 1644 | DP | Final Rejection | — | Pending | Jun 21, 2021 |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | STEELE, AMBER D | 1658 | §101§102§103§112DP | Final Rejection | 89d overdue | Pending | Feb 08, 2021 |
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | COFFA, SERGIO | 1658 | §103 | Final Rejection | 17d overdue | Pending | Jan 29, 2021 |
| 16817671 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | KIM, YUNSOO | 1641 | §112Other | Final Rejection | — | Pending | Mar 13, 2020 |
| 16208294 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT | HADDAD, MAHER M | 1641 | DPOther | Non-Final OA | — | Pending | Dec 03, 2018 |
| 14407174 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | HAVLIN, ROBERT H | 1626 | §103 | Final Rejection | 70d overdue | Pending | Dec 11, 2014 |
| 18687763 | IMMUNOFOCUS ASSAY FOR DETERMINING THE TITER OF DENGUE VIRUSES | BOESEN, AGNIESZKA | — | §103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18523331 | LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE | FOLEY, SHANON A | 1671 | §103§112DP | Non-Final OA | — | Pending | Nov 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial